To confirm whether CD82 inhibition of fibronectin-mediated EMT is dependent on fibronectin-receptor signaling events, we overexpressed wild-type FAK and ILK in prostate cancer cells through gene transfection. The gene discussed is CD82; the disease is prostate cancer.